CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company focused on developing innovative therapies for central nervous system disorders, specifically aggressive brain cancers. The company today announced its confidence in sharing the results from an interim analysis on one of its lead treatment candidates, Berubicin, with the public before the end of the year. Berubicin is a chemotherapy drug that interferes with the DNA of cancer cells to inhibit their growth and potentially shrink tumors. Distinct from other anthracyclines, a clinically trusted class of drugs in use for 60 years against dozens of common cancers, and other traditional chemotherapy drugs, CNS Pharmaceuticals reports that Berubicin has the ability to penetrate the blood-brain barrier and directly target cancer cells in the brain, increasing its potential effectiveness.

In October, the company announced that 229 out of 243 expected patients had already been enrolled in its ongoing study evaluating the effectiveness of Berubicin for recurrent glioblastoma ("GBM"), a highly aggressive and incurable form of brain cancer. The global critical and adaptive trial involves multiple centers and is open-label, randomized and controlled, comparing Berubicin to Lomustine - a drug unapproved for this indication but still used as the standard of care - in adult patients with recurrent GBM (WHO Grade IV) after standard first-line therapy has failed. CNS Pharmaceuticals had set a specific goal to analyze the efficacy data after more than half of the patients enrolled in the study reached the primary endpoint. During this analysis, an independent data safety monitoring board ("DSMB") closely examines the number of deaths in each treatment group to ensure that Berubicin patients show a significant improvement in overall survival compared to those receiving Lomustine. In addition, other important factors are considered, such as how long patients live without the cancer progressing, response rates and safety. The interim analysis will conclude if Berubicin is at least as effective as Lomustine, in which case the DSMB will make a recommendation that the trial continue.

To view the full press release, visit https://ibn.fm/2TGTx

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Thursday's trading session at $2.1, up 9.375%, on 170,932 volume. The average volume for the last 3 months is 420,192 and the stock's 52-week low/high is $0.6105/$6.597.

Recent News

• CNS Pharmaceuticals Inc. (NASDAQ: CNSP) - InvestorNewsBreaks - CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Release Interim Data by Year End for Lead Treatment Candidate Berubicin
• InvestorNewsBreaks - CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Q3 2023 Financial Results, Update on Berubicin Study
• Brain Cancer Reemergence Could Soon Be Detected Using a Finger-Prick Test

Clene Inc. (NASDAQ: CLNN)

The QualityStocks Daily Newsletter would like to spotlight Clene Inc. (NASDAQ: CLNN).

Clene recently released its financial results for the third quarter ended September 30, 2023, and provided recent operating highlights for its ALS clinical program

The ALS clinical program includes two independent studies evaluating the safety and efficacy of the company's lead investigational product CNM-Au8(R)

The 24-month long-term data cut from the open-label extension of the RESCUE-ALS study showed a significant median survival benefit of 19.3 months, a significant 52% decreased risk of ALS clinical worsening events, and a 75% decreased risk of long-term all-cause mortality

Clene also summarized long-term follow-up data from the HEALEY ALS platform trial, which demonstrated significantly improved survival among patients treated with CNM-Au8

The company closed Q3 2023 with $42.1 million in cash, cash equivalents, and marketable securities, expected to be sufficient to fund operations into Q3 2024

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of a pipeline of novel clean-surfaced nanotechnology therapeutics for the treatment of central nervous system disorders, including Amyotrophic Lateral Sclerosis ("ALS"), multiple sclerosis ("MS"), and Parkinson's disease ("PD"), recently released its financial results for the third quarter of fiscal 2023, ended September 30, and provided recent operating highlights for its ALS clinical program (https://ibn.fm/Y3sks).

Clene Inc. (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).

Its lead drug candidate is CNM-Au8®, an oral suspension developed to restore neuronal health and function by increasing energy production and utilization by driving critical cellular energy producing reactions that enable neuroprotection and remyelination to increase neuronal and glial resilience to disease-relevant stressors. CNM-Au8 is being studied in various clinical trials, including the Harvard/MGH Healey ALS Platform clinical trial for patients with ALS; RESCUE-ALS, a completed proof-of-concept clinical trial in patients with early symptomatic ALS; the REPAIR trials, completed target engagement clinical trials showing brain energy metabolite change with CNM-Au8; and a completed MS clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing MS. The company also has a nanotherapeutic platform of drug discovery.

CNM-Au8

CNM-Au8, Clene’s lead asset, is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals. Multiple pathogenic insults contribute to neuronal death. Mitochondrial dysfunction and NAD+ decline is a common final pathway in neurodegeneration, with NAD+ as a critical determinant of cell survival and function. CNM-Au8’s catalytic mechanisms target the energetic deficits, oxidative stress and accumulation of misfolded proteins that are common to many neurodegenerative diseases.

The unique catalytic mechanism of action of CNM-Au8 is hypothesized to act as a neuroprotective and remyelinating therapy in neurodegenerative disease states in order to: (1) drive, support and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed and/or damaged cells, (2) directly catalyze the reduction of harmful, reactive oxygen species (“ROS”) and (3) promote protein homeostasis via activation of the heat shock factor-1 pathway, recognized to dampen the cytotoxicity caused by misfolded and denatured proteins, which are known to occur ubiquitously in neurodegenerative diseases.

CNM-Au8 is used in combination with other agents, has no known drug-drug interactions, and is designed to improve function and survival. The clinical effects of both function and survival were seen in its clinical ALS trials, as earlier announced.

More than 500 estimated years of collective exposure across ALS, MS, and Parkinson’s disease participants in CNM-Au8 clinical trials and Expanded Access Protocol (compassionate use) programs have been recorded without any observed safety signals.

CNM-Au8 is a federally registered trademark of Clene Inc. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, began in 2013.

Market Opportunity

ALS is the most prevalent adult-onset progressive motor neuron disease, affecting approximately 30,000 people in the U.S. and an estimated 500,000 people worldwide, with a life expectancy of typically three to five years. Clene estimates that global ALS treatment sales will be greater than $1 billion annually within the coming few years. Additional treatments affecting daily function and survival remain the market need.

Additionally, there are more than 2 million MS patients globally, and Clene estimates the market size to be worth more than $23 billion annually. While the MS community has been successful at limiting relapses, non-relapsing MS patients continue to clinically deteriorate even while receiving effective immunomodulatory disease-modifying therapies (“DMTs”). A critical unmet medical need remains for therapeutic interventions that protect neuronal function and myelin health independent of immunomodulation to address progression independent of relapse activity.

Management Team

Robert Etherington is President, Director and CEO of Clene. He has more than 30 years of sales, marketing and leadership experience in the pharmaceutical industry. Prior to joining Clene, he worked at Actelion Pharmaceuticals, the largest biopharma company in the European Union prior to its acquisition by Johnson & Johnson in 2017, where he led that company’s U.S. commercial operations. He began his pharmaceutical sales and marketing career at Parke-Davis, a division of Pfizer, where he rose to the position of Team Leader overseeing the drug Lipitor.

Mark Mortenson is Chief Science Officer at Clene. He is co-inventor of the technology platform developed to produce the company’s therapeutics. He is the inventor or co-inventor on 32 other U.S. patents and hundreds of corresponding international patents. He is a former chief patent counsel responsible for 5,500 U.S. and international patents and patent applications. He holds bachelor’s degrees in physics and ceramic engineering from Alfred University, a master’s degree in materials science from Penn State University and a J.D. from George Washington University.

Benjamin Greenberg, M.D., MHS, FAAN, is Head of Medical at Clene. He is an internationally recognized expert in disorders of the central nervous system. He is currently professor of neurology and Vice Chair of Clinical and Translational Research in the department of Neurology at University of Texas Southwestern Medical Center in Dallas. He holds a bachelor’s degree from Johns Hopkins, a master’s degree in molecular microbiology and immunology from the Johns Hopkins School of Public Health and graduated from Baylor College of Medicine. He served residency in neurology at The Johns Hopkins Hospital.

Morgan R. Brown is CFO at Clene. He has more than 30 years of finance and accounting experience, with 23 years at biotech, pharmaceutical and medical device companies. He has served in similar roles at Lipocine Inc., Innovus Pharmaceuticals, World Heart Corp., Lifetree Clinical Research and NPS Pharmaceuticals Inc. He previously worked at accounting firm KPMG. He is a CPA with a bachelor’s degree in accounting from Utah State University and an M.S. in business administration from the University of Utah.

Clene Inc. (NASDAQ: CLNN), closed Thursday's trading session at $0.4599, up 4.2857%, on 104,336 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $6.597/$.

Recent News

• Clene Inc. (NASDAQ: CLNN) - Clene Inc. (NASDAQ: CLNN) Reports Q3 2023 Financial Results, Recent Operating Highlights for Its ALS Clinical Program
• Blood Test Could Detect Worsening MS Symptoms in Patients
• Clene Inc. (NASDAQ: CLNN) Among Grant Awardees Selected to Advance Scientific Research on ALS

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF)

The QualityStocks Daily Newsletter would like to spotlight FuelPositive Corp. (NHHHF).

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF), a Canadian-based, growth-stage company committed to providing commercially viable and sustainable, cradle-to-cradle, clean-energy solutions, has placed its initial purchase order with Cipher Neutron Inc. ("CN") for its unique Anion Exchange Membrane ("AEM") Electrolyser Technology. According to the announcement, CN's Green Hydrogen AEM Electrolysers combined with its reversible fuel cell technology can produce hydrogen without using any platinum group metals, including platinum, iridium and ruthenium. FuelPositive is using CN AEM Green Hydrogen Electrolyser Technology because its one of the most innovative, affordable and sustainable green-hydrogen solutions available for producing high-volume, high-pressure green hydrogen. The companies noted that, upon successful testing and benchmarking, the Cipher Neutron AEM Technology will be used to make green hydrogen to produce green ammonia in FuelPositive's commercial systems. "We are very excited to work with Canadian green-hydrogen innovator and manufacturer Cipher Neutron," said FuelPositive CEO and chair Ian Clifford in the press release. "FuelPositive is testing and benchmarking green-hydrogen technologies worldwide for our systems. We were happily surprised to find out that one of the most promising and impressive green-hydrogen technologies was here, right in our neighborhood. Teaming up with Canadian technology companies and supporting the Canadian economy as we build our green-ammonia solutions aligns with our mission as a company. If everything works out as expected, we hope this is the first of many transactions with Cipher Neutron."

To view the full press release, visit https://ibn.fm/7lmLe

FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF) is a growth stage company focused on licensing, partnership and acquisition opportunities building upon various technological achievements. The company is committed to providing commercially viable and sustainable clean energy solutions, including carbon-free ammonia (NH3), for use across a broad spectrum of industries and applications.

FuelPositive is headquartered in Toronto, Canada.

Hydrogen Economy Problems and FuelPositive’s Carbon-Free Technology

The hydrogen economy is currently facing many challenges. Traditional NH3 manufacturing exists on a massive scale, but centralized facilities result in some of the world’s most concentrated CO2 emissions. In total, an estimated 200 million metric tonnes of NH3 are consumed each year, with greater than 80% utilized by the agricultural sector. NH3 is also being positioned as a viable alternative to fossil fuels.

FuelPositive’s flagship carbon-free ammonia technology provides an innovative solution to these environmental concerns. Developed by Dr. Ibrahim Dincer and his team, the company’s platform allows for the in-situ production of NH3 in an entirely sustainable manner, using only water, air and sustainable electricity.

The production of hydrogen is energy intensive, but it is just one variable hindering the growth of the hydrogen economy. Other hurdles include:

• Storage – The storage of hydrogen by compression or liquification are both cost prohibitive and unsustainable.
• Distribution – The distribution network for effective hydrogen deployment has yet to be developed, as the extreme high-pressure distribution requirements to transport hydrogen would result in enormous infrastructure costs.
• End Use – R&D on the transportation-related end use applications for hydrogen is in its infancy, but almost any vehicle on the road today can be easily converted to run on NH3 at a considerably lower cost per mile traveled when compared to traditional fossil fuels.

A key benefit of FuelPositive’s patent-pending, first-of-its-kind carbon-free NH3 technology is its flexibility. The process allows for small, medium or large-scale production of NH3 on location, minimizing or even eliminating the challenges and volatility associated with storage and transportation to end use. As such, with an appropriately sized FuelPositive system and access to renewable energy, the end use applications for the company’s platform are nearly infinite.

Manufacturing Partnership

On May 19, 2021, FuelPositive announced its selection of National Compressed Air Canada Ltd. (“NCA”) to undertake manufacturing of the company’s Phase 2 hydrogen-ammonia synthesizer commercial prototype systems for carbon-free ammonia production.

In a news release detailing the partnership, FuelPositive CEO Ian Clifford noted, “This critical milestone for FuelPositive will confirm the broad application potential for our technology and is the backbone of our Carbon-Free Hydrogen-NH3 offering. Partnering with the knowledgeable and experienced team at NCA on this commercialization project will bring our development-stage program to life.”

Global Ammonia Market Outlook

The global ammonia market was valued at $52.71 billion in 2017 and is forecast to reach $81.42 billion by 2025, growing at a CAGR of 5.59%, according to data from Fior Markets (https://ibn.fm/1OfOB).

The agricultural industry consumes more than 80% of global NH3. Smaller percentages can be attributed to the waste, water treatment, refrigerants, antiseptic, textile, mining and pharmaceutical industries.

One of the most polluting industries on the planet consists of conventional agribusinesses. These polluters are responsible for more greenhouse emissions per year than transportation. This is where FuelPositive’s technology is expected to be extremely beneficial.

Management Team

Ian Clifford is Director, CEO and Founder of FuelPositive Corp. He has over 25 years of experience in the fields of technology and marketing and has successfully led the company to global brand recognition through its unique energy solutions. Since 2006, Mr. Clifford has raised over $50 million in equity financing for FuelPositive. He also co-founded digIT Interactive, a full-service internet marketing company serving Fortune 500 clients, which he sold at the peak of the market in 2000.

Greg Gooch serves as a Director and President of FuelPositive. His multifaceted career in the electronics and finance industries has positioned him as a key advisor and funding partner to start-ups and new technology companies for over 40 years. Mr. Gooch has been involved with FuelPositive since its early days and has remained a significant supporter and consultant to the company over the years. He has a bachelor’s from McGill University and an MBA from the University of Western Ontario.

Dr. Ibrahim Dincer is a scientific advisor to FuelPositive and is recognized as a pioneer and international leader in the area of sustainable energy technologies. Along with his team, Dr. Dincer invented the modular carbon-free ammonia (NH3) production technology that FuelPositive is commercializing. His area of specialty covers various topics including ammonia, hydrogen energy and fuel cells; renewable energy systems; energy storage systems and applications; carbon capturing technologies, and integrated and hybrid energy systems He is currently managing an exemplary team of researchers in this commercialization project.

Marek Warunkiewicz is the company’s Communications & Branding Specialist. He brings more than 40 years of entrepreneurial expertise to the FuelPositive team, having held marketing, branding, advertising, project management and graphic design positions with various companies. Mr. Warunkiewicz has successfully created business-to-business marketing and advertising campaigns for a diverse group of clients ranging from high-tech to agriculture. He co-founded digIT Interactive and ZENN Motor Company alongside Ian Clifford.

Luna Clifford is the Director of Communications for FuelPositive. She has over 10 years of experience as a business owner and advisor, helping build and operate several successful start-up enterprises while managing complex stakeholder relationships. Ms. Clifford excels in strategic planning and team building, and she has completed extensive studies in the fields of communications and health care.

FuelPositive Corp. (NHHHF), closed Thursday's trading session at $0.05, off by 7.2356%, on 3,532,739 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.035/$0.1348.

Recent News

• FuelPositive Corp. (TSX.V: NHHH) (OTC: NHHHF) - InvestorNewsBreaks - FuelPositive Corporation (TSX.V: NHHH) (OTCQB: NHHHF) Partners with Cipher Neutron to Offer Green-Energy Solution
• InvestorNewsBreaks - FuelPositive Corporation (TSX.V: NHHH) (OTCQB: NHHHF) Invited by Canadian Government to Be Key Part of Rebuild Ukraine Delegation
• Government of Canada Invites FuelPositive to Join Rebuild Ukraine Delegation

Appia Rare Earths & Uranium Corp. (CSE: API) (OTCQX: APAAF)

The QualityStocks Daily Newsletter would like to spotlight Appia Rare Earths & Uranium Corp. (CSE: API) (OTCQX: APAAF).

Appia (CSE: API) (OTCQX: APAAF) (FSE: A0I0) today announced that it is reevaluating its large uranium-rare earths deposits located at Elliot Lake, Ontario, to examine the impact of increased uranium prices and confirmation of significant rare element ("REE") mineralization. According to the announcement, the company will also evaluate the cost-saving potential of bulk mining the Teasdale Lake and Banana Lake Zones. In 2007-08 and 2012, Appia completed drill programs to confirm mineralization detailed in historical resource estimates for these zones, after which it engaged consulting firm Watts, Griffis and McOuat Limited ("WGM") to provide an updated NI 43-101 Resource Estimate. The technical report was prepared in accordance with the provisions of National Instrument 43-101 and filed on SEDARplus on Aug. 14, 2013.

To view the full press release, visit https://ibn.fm/tpYsC

Appia Rare Earths & Uranium Corp. (CSE: API) (OTCQX: APAAF) is a mineral exploration company focused on exploration activities at its newly acquired Cachoeirinha rare earths project (“PCH Project”) in Brazil, as well as delineating high-grade critical rare earth elements (REE) and gallium at its Alces Lake property in Saskatchewan. Other properties in Appia’s portfolio include its Elliot Lake Property in Ontario’s historic mining camp, with a large NI 43-101 uranium and rare earths resource. Fully funded with over $5 million (CDN) in cash, no debt, aggressive exploration currently underway, and experienced management, Appia is progressing rapidly on multiple fronts in highly desired market sectors.

The company is headquartered in Toronto, Canada.

Projects

PCH Project-Brazil

The PCH project hosts REE mineralization in both ionic clays developed from the weathering of alkaline granites and in-situ rare earth mineralization associated with the underlying granite and a carbonatite intrusion to depths greater than 100 meters. Sampling data shows enrichment in rare earth minerals to depths of between eight meters and +30 meters.

In early 2023, Appia announced a definitive agreement to acquire a 70% interest in the PCH Project, which is 17,551 hectares in size and located in the Tocantins Structural Province of the Brasília Fold Belt, Goiás State, Brazil. It is classified as an alkaline intrusive rock occurrence with the potential for highly anomalous REE and Niobium mineralization.

The region around Iporá, a city located roughly 30 km from the PCH Project, has significant mineral exploration and mining activity and well-developed infrastructure.

In July 2023, Appia commenced an aggressive auger and reverse circulation (RC) drill campaign to delineate a potential resource estimate at the PCH project. Initial results at the site revealed significant exploration potential with impressive values that often surpass known ionic clay deposits in Brazil, particularly for the highly valuable heavy rare earths Terbium and Dysprosium.

The auger holes drilled at Target 4 have exhibited a range of total REE grades, ranging from 274 ppm to 16,648 ppm (1.66%), with an average of 1,291 ppm total REE. The valuable rare earths used in magnet applications – praseodymium, neodymium, terbium and dysprosium (Pr, Nd, Tb, and Dy) plus yttrium (Y) accounted for approximately 14% of total rare earths, reaching a maximum of 28.4%. Notably, the deposit also contains anomalous values of niobium and scandium, with average values of 736 ppm for Nb and 62 ppm for scandium in a composite sample from Target 4.

Heavy rare earths (HREEs) show maximum values of 1,624 ppm and average values of 1,291 ppm, primarily as terbium and dysprosium. Light rare earths (LREEs) show maximum values of 14,024 ppm (1.54%) with an average of 1,145 ppm. Neodymium and praseodymium, the main magnetic light rare earths, show respective maximum values of 3,131 ppm (Nd) and 885 ppm (Pr) and average values of 216 ppm (Nd) and 61.7 ppm (Pr). The overall HRRE/LREE ratio has a maximum of 39.5% and an average value of 16.67%.

“Appia is thrilled with the progress made and the promising results thus far,” CEO Tom Drivas stated in a news release. “The company remains committed to advancing its exploration plans, aiming to promptly gather significant data throughout the year, and to work towards estimating a maiden mineral resource in the coming months.”

Alces Lake Project – Saskatchewan

Appia’s Alces Lake project, located in northern Saskatchewan, encompasses some of the highest-grade total and critical REEs and gallium mineralization in the world, hosted within several surface and near-surface monazite occurrences that remain open at depth and along strike.

Following the company’s acquisition of additional new mineral claims in the area in February 2023, Appia’s Alces Lake claim block now totals 38,522 contiguous hectares (95,191 acres) – 100% owned by the Company.

Appia announced the completion of a NI43-101 technical report on the property in June 2023, providing an update on exploration previously reported in March 2021.The report is available on SEDAR under the company’s profile.

Extensive diamond drilling and geophysics surveys are underway to explore a more than 25-kilometer structural corridor. In July 2023, the company issued an update on its diamond drill program having completed the first phase of drilling at the project’s Magnet Ridge Zone to further test the extent of the mineralization to the south south-east (SSE). President Stephen Burega noted the presence of “continued mineralization at significantly thicker intercepts.”

As part of its 2023 exploration program at Alces Lake, Appia plans to target priority areas that extend SSE from the Wilson, Richard, Charles, Bell, Ivan, Dylan, Dante and AMP zones through the Magnet Ridge Zone and beyond, covering an area extending approximately 20 kilometers in length and 5 to 7 km in width. Appia will also undertake reconnaissance drilling on priority regional geological and geophysical targets in the Western Anomaly area.

Other Projects

• Appia holds a total of 75,314 hectares (186,106 acres) of land on four uranium claim blocks in the prolific Athabasca Basin (Loranger, North Wollaston, Eastside and Otherside). Exploration plans for these properties are expected to be announced once permits are in hand.
• Appia also has a 100% interest in 12,545 hectares (31,000 acres), with rare earth element and uranium deposits over five mineralized zones, in the Elliot Lake Camp, Ontario.

Market Opportunity

A report from Mordor Intelligence forecasts the global REE market is expected to grow from 168 million tons in 2023 to 206.25 million tons by 2028, marking a CAGR of 4.19% during the forecast period. The market is gradually improving following the economic and production restrictions of the COVID-19 pandemic.

Factors driving the market’s growth include high demand from emerging economies and the dependency of environmentally friendly technologies on rare earth elements.

According to UxC, one of the nuclear industry’s leading market research and analysis companies, the uranium market is rapidly becoming production-driven, where spot and long-term prices more closely correlate to the marginal cost of uranium production.

Although global reactor requirements are projected to be flat through 2024, UxC forecasts that significant demand growth from 2025 to 2040 will necessitate new production as resources are exhausted at several uranium projects. In addition, a large percentage of production exists in regions of the world with high geopolitical risk, which makes the market vulnerable to future disruptions and price volatility.

Management Team

Tom Drivas is CEO of Appia Rare Earths & Uranium Corp. He is an entrepreneur with over 30 years of experience in various industries, including over 20 years in the mineral resource industry. He is also currently a director of Romios Gold Resources Inc., a publicly traded company he founded in 1995.

Stephen Burega is President of Appia. He brings 16 years of management and operations experience in the mining and natural resources sectors. His extensive emerging markets background, along with a deep understanding of stakeholder management, social development and structured community engagement, position him well to lead Appia’s First Nations community engagements. He is also President and CEO of Romios Gold Resources which is focused on base and precious metal exploration in North America.

Frank van de Water is the company’s CFO. He holds CPA and CA designations and has been involved with international mining, metals and resource companies in North America, Latin America, Europe and Africa for more than 40 years.

Dr. Irvine R. Annesley, Ph.D., is VP Exploration at Appia. He is a licensed geoscientist (P.GEO.) and Professor in Economic (Mining and Mineral Exploration) Geology at École Nationale Supérieure de Géologie in France and an Adjunct Professor in Geology at the University of Saskatchewan. He has over 35 years of global exploration and applied research experience in uranium, gold and base metals exploration, most recently with Athabasca uranium explorer JNR Resources Inc.

Don Hains, P.Geo., is the company’s Consulting Geologist and Qualified Person Consulting Industrial Minerals Expert.

Antonio Vitor is Appia’s Country Manager, Brazil. He has a track record as a portfolio manager and board member. He has held multiple significant positions, including Territory Manager at Shell, as well as Senior Project Planning and Consulting roles at PwC and Petrobras.

Jack Lifton is the company’s Senior Technical Advisor and Consultant. He is an author and lecturer on the market fundamentals of technology metals.

Appia Rare Earths & Uranium Corp. (OTCQX: APAAF), closed Thursday's trading session at $0.172, up 9.2063%, on 217,635 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.075/$0.34495.

Recent News

• Appia Rare Earths & Uranium Corp. (CSE: API) (OTCQX: APAAF) - InvestorNewsBreaks - Appia Rare Earths & Uranium Corp. (CSE: API) (OTCQX: APAAF) (FSE: A0I0) Revisits Potential of Elliot Lake Deposits and Bulk Mining Two Zones
• InvestorNewsBreaks - Appia Rare Earths & Uranium Corp. (CSE: API) (OTCQX: APAAF) (FSE: A0I0) Releases New Drilling Results from PCH Ionic Clay Project
• InvestorNewsBreaks - Appia Rare Earths & Uranium Corp. (CSE: API) (OTCQX: APAAF) (FSE: A0I0) Announces Significant Milestone for Its PCH Project in Brazil

Mountain Top Properties Inc. (OTC: MTPP)

The QualityStocks Daily Newsletter would like to spotlight Mountain Top Properties Inc. (OTC: MTPP).

Mountain Top Properties (OTC: MTPP), a diversified real estate holding company that acquires, sells and operates assets through its wholly owned subsidiaries and limited partnerships, today announced that it has selected IBN, a multifaceted financial news and publishing company for private and public entities, to assist with its corporate communications initiatives. Mountain Top Properties specializes in property management, property technology ("PropTech") and real estate redevelopment. The company's flagship subsidiary is Mountain Top Realty Inc., the managing partner of Mountain Top Capital Fund I LLC, a New York limited liability company focused on residential redevelopment in the prestigious and storied Hamptons, New York, beachfront communities. As part of the client-partner relationship, IBN will leverage its investor based distribution network of 5,000+ key syndication outlets, various newsletters, social media channels, wire services via InvestorWire, blogs and other outreach tools to generate greater awareness for Mountain Top Properties.

To view the full press release, visit https://ibn.fm/lN0TZ

Mountain Top Properties Inc. (OTC: MTPP) is a diversified real estate holding company that acquires, sells and operates assets through its wholly owned subsidiaries and limited partnerships. The company specializes in property management, property technology (“PropTech”) and real estate redevelopment.

Mountain Top Properties was incorporated in 1990 and is based in Liverpool, New York, with offices in Sag Harbor, New York.

Organization

The company’s flagship subsidiary is Mountain Top Realty Inc., the managing partner of its first real estate fund focused on residential redevelopment in the prestigious and storied Hamptons, New York, beachfront communities.

Mountain Top Properties is also the lead investor in blockchain-enabled industrial and warehouse flex space HQXpress, which services the warehousing, reverse logistics and liquidation markets.

The company is in negotiations for the addition of AI-powered technologies that promise to simplify real estate services, including purchasing and sales.

Mountain Top Capital Fund I LLC

Mountain Top Capital Fund I LLC is a New York limited liability company recently organized by affiliates of Mountain Top Realty, manager of the fund. Through this fund, Mountain Top Realty will leverage the company’s experience, market conditions and industry relationships to capitalize on real estate projects as they arise.

This partnership will be focused on waterfront or water view properties in the Hamptons. The Hamptons market has historically remained strong and continues to set new highs year over year.

The fund has partnered with On Site Builder Construction Co. Inc., which is managed by Joseph Kelley, who, for over 40 years, has continued to build the highest quality architecturally designed custom houses, varying in style from classic to ultra-modern, in the Hamptons. Several houses he has built are showcased in books and magazines and featured across various forms of digital and social media. His assembled team of skilled subcontractors are among the finest skilled craftsmen in their various fields of expertise.

Mr. Kelley has built over 60 custom homes in this market and has the unique distinction of building the most expensive house sold in Sag Harbor in 2014, which sold for $31,750,000; the most expensive house in the Hamptons in 2019, which first sold for $27,500,000 in 2017 and later was renovated and re-traded for $39,250,000; and the most expensive house sold in the Hamptons in 2022, which sold with the neighboring house for $118,500,000. Mr. Kelley’s portfolio of projects is valued at over $400,000,000. Although he has historically worked as a custom home builder, he would like to shift from providing a service to now providing a finished product in this market.

Market Opportunity

Mountain Top Capital Fund I has a target to raise $75 million to acquire, renovate and remarket Hamptons waterfront or water view properties. The fund has secured debt capital commitments for 70% of the acquisition costs and 100% of the construction costs and will use $10 million to leverage strategic waterfront opportunities in and around the Hamptons.

Profits from each project will be distributed upon the sale of the project, which is anticipated every 15 to 18 months, with a target of a minimum return on investment of 20% to 30% per transaction.

The company anticipates the fund’s Hamptons projects will be followed up by several other funds targeting additional high-end markets.

Management Team

Beau Kelley is CEO, President, CFO and Director of Mountain Top Properties.

Mountain Top Properties Inc. (OTC: MTPP), closed Thursday's trading session at $0.12, up 120.1835%, on 241,597 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0064/$0.12.

Recent News

• Mountain Top Properties Inc. (OTC: MTPP) - InvestorNewsBreaks - Mountain Top Properties Inc. (MTPP) Engages IBN for Corporate Communications Expertise
• InvestorNewsBreaks - Why Mountain Top Properties Inc. (MTPP) Is 'One to Watch'
• Mountain Top Properties Inc. (MTPP) Is 'One to Watch'

Diamond Lake Minerals Inc. (OTC: DLMI)

The QualityStocks Daily Newsletter would like to spotlight Diamond Lake Minerals Inc. (OTC: DLMI).

Diamond Lake Minerals is multi-strategy operating company focused on building, acquiring and developing companies within a wide variety of industries

DLMI's strategy involves bridging generations of investors with accessible digital investment technology in sectors ranging from music and entertainment to real estate, healthcare and digital tokens

Security token-centered ecosystems are gaining traction around the world, providing digital alternatives to traditional investments such as stocks or bonds — digital investments that may nonetheless deliver rights to assets that have real value

DLMI is conscientious about the need to comply with SEC regulations and provide transparency to its shareholders, drawing on the decades of experience held in reserve by the company's executive team

Diamond Lake Minerals (OTC: DLMI), a leading multistrategy operating company specializing in the development and support of digital assets and SEC-registered security tokens, was spotlighted in a recent Benzinga article. The article, titled "How Diamond Lake Minerals Pivoted from Its Minerals Roots to Digital Assets — And What This Means for the Future of Digital Securities," provides an overview of how Diamond Lake Minerals has positioned itself as a leader in tokenization. According to the article, tokenization is a fundamental shift in markets capable of catalyzing the next generation of finance. Leveraging tokens means that financial transactions can achieve immediate settlement while lowering fees and removing the cumbersome processes of clearing and settlement.

The article notes the key role that DLMI's management team has played as the company has "strategically pivoted to become a trailblazer in digital assets and SEC-registered security tokens." The article also observed the critical role that the INX Digital Company has played as a Diamond Lake Minerals partner; INX provides a regulated trading platform for digital securities that operates around the clock. "Diamond Lake Minerals and its great working relationship with INX are emblematic of the industry's progressive shift toward a digital-first approach in finance," the article states. "By managing a diverse portfolio of subsidiaries and embracing digital assets and security tokens, the company hopes to deliver consistent earnings and shareholder value as a long-term savings vehicle similar to General Electric Company. Diamond Lake Minerals represents the fusion of time-honored business values with innovative digital strategies, set to harness the full potential of tokenization in financial markets. Its forward-thinking leadership, strategic partnerships and commitment to regulatory compliance establish it as a formidable force in the growing market of digital assets and security tokens."

To view the full article, visit https://ibn.fm/TBDjF

Diamond Lake Minerals Inc. (OTC: DLMI) is a multi-strategy operating company offering traditional investors an entry point to the future of digital securities. The company’s goal, through its established M&A roadmap, is to responsibly innovate and develop promising businesses that are likely to benefit from the ongoing shift toward digital assets. Through this approach, Diamond Lake Minerals provides traditional investors an opportunity to gain exposure to the emergence of regulated digital securities through a more familiar investment vehicle – the purchase of stock.

Founded in 1954 and headquartered in Salt Lake City, Diamond Lake Minerals is positioning itself as a leader in the digital asset and security token space. The company’s mission is to bring back to the public markets timeless business principles focused on healthy, sustainable growth and strong earnings with a goal of creating value for stakeholders in the modern digital world.

Diamond Lake Minerals believes the future of financial markets is set to be revolutionized by tokenization. Tokenization refers to the use of digital assets that can be traded via protocols with instantaneous settlement and reduced fees, eliminating the need for traditional clearing or settlement processes. Beyond efficiency, the emerging landscape emphasizes transparency, liquidity and security in asset management and investment.

With the backing of Esposito Intellectual Enterprises and its 20+ years of experience, Diamond Lake Minerals has access to the expertise of 110+ companies and 200+ joint ventures, along with knowledge spanning 25+ industries. The company is creating a vertically integrated ecosystem that encompasses various high-growth sectors. This integration aims to maximize operational efficiencies and profitability across all business units.

Products & Services Portfolio

Diamond Lake Minerals, guided by its strategic partnerships and future roadmap, envisions a diverse portfolio across multiple industries, as shown in the overview below. The company is poised to redefine the conglomerate model for the 21st century, with a focus on vertical integration, digital securities and sustainable growth.

Its target market segments include:

• Fashion: DLMI seeks stakes in brands blending timeless aesthetics with tech influences.
• Beauty: DLMI eyes partnerships with innovators elevating beauty through sustainable practices.
• Real Estate: DLMI aims for interests in ventures modernizing property transactions via blockchain.
• Hospitality: DLMI’s vision includes associations with enterprises enhancing guest experiences via tech integration.
• Liquor: DLMI aspires to collaborate with unique distillers merging tradition and innovation.
• IoT: DLMI intends to invest in solutions seamlessly connecting the digital and physical worlds.
• Wireless: DLMI envisions stakes in wireless tech optimizing global communication.
• Technology: DLMI plans to back pioneers driving the next tech revolution.
• Maritime: DLMI seeks partnerships in maritime solutions emphasizing green initiatives.
• Aviation: DLMI’s strategy includes holdings in aviation innovators focusing on efficiency.
• Aerospace: DLMI aims to support ventures pushing boundaries in space exploration.
• Education: DLMI collaborates with platforms revolutionizing learning through tech.
• Charity: DLMI eyes alliances with charitable entities leveraging transparency via blockchain.
• Healthcare: DLMI foresees investments in healthcare tech personalizing patient care.
• TV: DLMI intends stakes in TV platforms innovating content delivery.
• Film: DLMI aspires to support filmmakers merging storytelling with immersive tech.
• Music: DLMI plans interests in music ventures amplifying artists through digital platforms.
• Entertainment: DLMI targets stakes in platforms redefining entertainment paradigms.
• IP: DLMI envisions collaborations safeguarding intellectual properties via tech solutions.
• Data Management: DLMI seeks ventures optimizing data utilization and insights.
• Data Storage: DLMI’s roadmap includes alliances with secure data storage solutions.
• Streaming: DLMI intends to back streaming platforms prioritizing user experience.
• Real World Assets: DLMI eyes investments translating tangible assets into digital value.
• Gold & Silver: DLMI aims for stakes in platforms digitizing precious metal trading.
• Sports: DLMI envisions collaborations enhancing sports experiences via tech integration.
• Sports Technology: DLMI seeks ventures revolutionizing athlete performance and fan engagement.
• Water: DLMI plans to back solutions ensuring water sustainability and accessibility.
• Water Treatment: DLMI targets investments in eco-friendly water purification technologies.
• Animation: DLMI eyes stakes in animation houses blending art with cutting-edge tech.
• Studio Production: DLMI’s vision includes support for studios transforming content creation.
• Consumer Products: DLMI seeks partnerships with brands prioritizing consumer-centric innovations.
• Collectables: DLMI envisions collaborations with platforms digitizing unique collectibles.
• Digital Assets: DLMI aims to invest in ventures maximizing the potential of digital ownership.
• Web3: DLMI aspires to back pioneers ushering in the decentralized web era.
• Identity Management: DLMI eyes solutions prioritizing user identity security in the digital space.
• Media & Journalists: DLMI seeks alliances promoting unbiased reporting and content democratization.
• Metaverse: DLMI envisions stakes in ventures crafting immersive virtual universes.
• Space Economy: DLMI targets investments in ventures monetizing space exploration.
• Modular Homes: DLMI plans interests in solutions revolutionizing home construction.
• Financial Technology: DLMI seeks partnerships modernizing financial transactions.
• Gaming: DLMI aims to back game developers enhancing user immersion.
• Travel: DLMI eyes collaborations transforming travel experiences through tech.
• Health & Wellness: DLMI’s strategy includes investments in holistic health tech solutions.
• Augmented Reality: DLMI envisions stakes in AR platforms blurring reality and digital.
• AI: DLMI seeks to support AI innovations humanizing tech interactions.
• Esports: DLMI targets investments in platforms amplifying esports experiences.
• Construction: DLMI plans to back ventures modernizing construction practices.
• Virtual Reality: DLMI intends stakes in VR platforms offering alternate realities.
• Retail Tech: DLMI envisions collaborations digitizing retail experiences.
• Biotechnology: DLMI seeks ventures pushing boundaries in biotech innovations.

Market Opportunity

According to Diamond Lake Minerals’ business plan executive summary, the market for digital securities is projected to grow from $10 billion in 2022 to $1 trillion by 2028, a CAGR of 45% for the forecast period.

The global blockchain market value is expected to grow from an estimated $3 billion in 2020 to $39.7 billion by 2025, marking a CAGR of 67.3% for the period. Valued at $2.28 billion in 2021, the Security Token Offerings market is projected to grow at a CAGR of 19%. This growth is expected to be driven by the rising adoption of tokenization and the increasing prominence of STOs, especially in North America.

In addition, the global investment management market is projected to grow from a value of $100 trillion in 2020 to $178 trillion by 2025, recording a CAGR of 7.2% over the period.

Management Team

Brian J. Esposito is CEO of Diamond Lake Minerals. As founder and CEO of Esposito Intellectual Enterprises LLC, he brings over 20 years of diverse experience in sectors like manufacturing, technology, music and real estate, and is known for his global executive networking and balance sheet optimization skills.

Michael Reynolds is President and Director of Diamond Lake Minerals. With 35 years in private finance and M&A, he has been instrumental in growing companies like Herbalife through reverse acquisition, as well as elevating JB Oxford to $120 million in revenue. His expertise in operational management and business development ensures professional solutions for clients’ business interests.

Jon Karas is DLMI’s senior transaction and investment executive. As the CEO and co-founder of Akon Legacy Ventures, he structured, negotiated and closed numerous transactions focused on innovation and social impact in smart cities, blockchain, agriculture, mining and technology. He co-founded and led multiple companies in media and entertainment and was the driving force behind the development, financing and production of a broad range of film and television content.

Advisory Board

Anthony Scaramucci, Founder and Managing Partner of SkyBridge Capital and Chairman of SALT, brings to Diamond Lake Minerals unparalleled expertise in finance, technology and business strategy. He is expected to be instrumental in shaping DLMI’s strategic direction as the company continues to redefine the future of traditional and digital securities.

Larry Namer, Founder of E! Entertainment TV and President of Metan Global, boasts a remarkable career spanning more than half a century. He is an esteemed veteran of the entertainment industry, renowned for his influential contributions to cable television, live events, music and new media. He also leads LJN Media, a consulting firm known for its cross-industry expertise in technology, business and finance.

Andrew Fromm is a seasoned CEO and consultant with a focus on music publishing. He is known for his expertise in asset sales, songwriting and artist development. His extensive network extends beyond the music industry, showcasing his versatility and authority in the field.

Brandon Fugal is the Chairman of Colliers International in Utah and a former EY Entrepreneur of the Year. He has co-founded multiple ventures, including Coldwell Banker Commercial Advisors, Cypher, Axcend and Texas Growth Fund, and he is a recognized authority in real estate and entrepreneurship.

Michael Malik Sr. is a Detroit-based entrepreneur with a $750 million net worth, known for his pivotal role in legalizing gambling and developing major casino projects across the U.S., including Detroit’s MotorCity Casino and various Native American gaming ventures. He brings to Diamond Lake Minerals a wealth of experience and a proven track record in the gaming, sporting and entertainment industries spanning over five decades.

Raul Leal is an experienced CEO in the hospitality sector, known for his visionary leadership at SH Hotels & Resorts and former role at Virgin Hotels, where he secured over $500 million in funding and revolutionized guest experiences.

Agnes Budzyn, an accomplished entrepreneur and CEO of Bluedge Ventures, brings to the company a rich history in traditional finance and blockchain technology, serving on various global boards and committees. She has been recognized by the World Economic Forum and numerous institutions for her expertise and contributions to bridging legacy finance with emerging digital asset infrastructure.

Diamond Lake Minerals Inc. (OTC: DLMI), closed Thursday's trading session at $3.9, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.35/$3.90.

Recent News

• Diamond Lake Minerals Inc. (OTC: DLMI) - InvestorNewsBreaks - Diamond Lake Minerals Inc. (DLMI) Featured in Recent Benzinga Article as 'Trailblazer' in Digital Assets, Security Tokens
• Diamond Lake Minerals Inc. (DLMI) Building Value for Investors with Focus on STO Frontier, Other Digital Assets
• InvestorNewsBreaks - Diamond Lake Minerals Inc. (DLMI) CEO Talks Bridging Gap Between Traditional Market and Future of Digital Securities on Benzinga's All-Access

PaxMedica Inc. (NASDAQ: PXMD)

The QualityStocks Daily Newsletter would like to spotlight PaxMedica Inc. (NASDAQ: PXMD).

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, is reporting on its financial results as well as providing a comprehensive business update for the third quarter ended Sept. 30, 2023. Highlights of the report include the successful conclusion of a crucial Type-B meeting with the U.S. Food and Drug Administration designed to gather vital guidance for the NDA submission of PAX-101; the completion of the final PAX-101 phase 3 trials for human African trypanosomiasis (HAT); the strategic acquisition of suramin research assets from Rediscovery Life Sciences (RLS); and the successful completion of a commercial-scale development plan for PAX-101, which shows the company is on track for manufacturing API validation, drug-product validation and registration lots in the first quarter of 2024. The company's financial report showed a total of $1.2 million in cash reserves with access to the remaining $14.4 million from the company's committed equity investment agreement, with a total count of common shares issued and outstanding as of the end of the quarter reaching 1,073,815. "The accomplishments in the third quarter of 2023 represent significant progress in our journey towards a 2024 US FDA filing of an NDA for the treatment of HAT with PAX-101 (IV suramin)," said PaxMedica CEO Howard Weisman in the press release. "The favorable results from our retrospective HAT-301 study reinforce the substantial benefits of suramin in treating this life-threatening infection. With these milestones, PaxMedica is well-positioned to expand our research initiatives, including the exploration of PAX-101 for addressing the core symptoms of autism spectrum disorder."

To view the full press release, visit https://ibn.fm/ytu1j

PaxMedica Inc. (NASDAQ: PXMD) is a clinical stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (APTs) for the treatment of Autism Spectrum Disorder (ASD) and other serious conditions with intractable neurologic symptoms.

The company’s lead programs are focused on ASD, for which there are currently no approved pharmacologic treatments that target its cause and symptoms. Currently used treatments only address the symptoms of the condition, rather than targeting the pathophysiology itself.

PaxMedica is on a promising path to address these unmet medical needs, bringing hope to millions. Anti-purinergic therapies target the excess production of purines in cells. An overexpression of purines can offset homeostasis and result in an overproduction of cellular adenosine triphosphate, the main energy molecule in all living cells.

The company is headquartered in Tarrytown, New York.

Product Pipeline

PaxMedica is building a robust pipeline of products targeting ASD and related neurodevelopmental conditions. The company’s lead product in development may help eliminate, reduce or modulate some of the more troublesome aspects of ASD. That would open the potential for people with autism to integrate their behavior with others more successfully and improve their lives.

PaxMedica’s lead programs, PAX-101 and PAX-102, utilize the company’s proprietary source of suramin sodium, a broadly acting anti-purinergic therapy that has been known for over 100 years. Its current pipeline includes:

• PAX-101 (IV Suramin) for ASD – PAX-101 completed a Phase 2B study for ASD in 2021. Suramin is a broadly acting APT and has reported positive results from a dose range study. The results of PaxMedica’s Phase 2B study, which targeted 52 subjects across six sites in South Africa, were presented to AACAP in October 2021.
• PAX-102 (Intranasal Suramin) – PaxMedica has developed a proprietary intranasal formulation of suramin that is currently being evaluated in ASD and other neurodevelopmental conditions.
• PAX-101 for HAT – Given suramin’s historical use as a treatment for Human African Trypanosomiasis (HAT), or African Sleeping Sickness, the company is also developing PAX-101 as a treatment for HAT. PaxMedica’s most advanced program is the pursuit of PAX-101 for early-stage East African HAT.
• Selective APTs – PaxMedica has conducted several preclinical studies to evaluate other APTs that are more selective to specific purinergic receptors and may offer additional benefits over suramin.

Market Opportunity

According to a report by Fortune Business Insights, a leading global market research company, the global ASD therapeutics market was estimated at $1.93 billion in 2022 and is projected to grow from $2.01 billion in 2023 to $3.42 billion by 2030, a CAGR of 7.9% over the forecast period. As there is no current treatment for the core symptoms of autism, PaxMedica believes the addressable market for PAX-101, if approved, could greatly exceed these forecasts.

Autistic disorder, Asperger’s Syndrome and Pervasive Development Disorder are the three main types of ASD, affecting millions of people globally. A 2020 report by the U.S. Centers for Disease Control & Prevention estimated that one in 36 children in the U.S. have been diagnosed with autism disorder.

Several factors are expected to contribute to market growth prospects. A growing prevalence of the condition globally and rising awareness coupled with available treatment options are key factors expected to drive ASD therapeutics market growth during the forecast period. Growing investment in R&D to find effective treatments is also expected to fuel global market growth.

Management Team

Howard Weisman is Chairman and CEO of PaxMedica. He has been a founder and CEO of several specialty pharma and medical device companies. Most recently, he was executive chairman and co-founder of Sofregen, a biotech company. He also served as CEO and president of Seventh Sense Biosystems, a medical device development company. He also was founder, chairman and CEO of EKR Therapeutics, a specialty pharmaceutical company, and founder and COO of ESP Pharma, a company focused on cardio and neurovascular products. He has a bachelor’s degree in chemistry from Rutgers University.

David Hough, M.D., is Chief Medical Officer at PaxMedica. He is a neuroscience clinical development consultant who previously served as vice president at Janssen Research and Development and in various leadership roles over 17 years. Most recently, he was the compound development team leader for SPRAVATO® for treatment-resistant depression. Prior to that, he was the schizophrenia disease area leader. He played a pivotal role in the development programs for oral INVEGA®, INVEGA SUSTENNA® and XEPLION® for schizophrenia. He is a graduate of West Point and is board certified in psychiatry.

Stephen Sheldon is COO and CFO at PaxMedica. He has served as CEO of Thailand-based specialty healthcare company Indochina Healthcare Co. Ltd. since 2015. Previously, he was a consultant for PricewaterhouseCoopers Healthcare Advisory in the Chicago office. He was responsible for developing specialty pharmacy patient programs, strategy development for specialty products and compliance programs. He has an MBA from Thunderbird School of Global Management and a bachelor’s degree in computer science and visual arts from Bowdoin College.

PaxMedica Inc. (NASDAQ: PXMD), closed Thursday's trading session at $2.02, off by 16.5289%, on 962,776 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.6545/$69.19.

Recent News

• PaxMedica Inc. (NASDAQ: PXMD) - InvestorNewsBreaks - PaxMedica Inc. (NASDAQ: PXMD) Releases Q3 2023 Financial Report, Corporate Update
• PaxMedica, Inc. Announces Third Quarter 2023 Financial Results and Business Update
• PaxMedica Inc. (NASDAQ: PXMD) Is Hoping to Boost Patient Independence with Potential ASD Treatment Amid Growing Prevalence Rates

Longeveron Inc. (NASDAQ: LGVN)

The QualityStocks Daily Newsletter would like to spotlight Longeveron Inc. (NASDAQ: LGVN) .

Toxoplasma gondii (T. gondii) is a single-cell parasite that can cause severe physical and mental conditions. This parasite is known to trigger risky behavior in hosts. The most common way for an individual to be exposed to this parasite is when disposing of cat litter. This is because while the parasite does affect rodents and birds, it thrives in cats. In felines, it can multiply in the cat's intestines, with its eggs being excreted for easier and faster transmission. While the parasite can stay alive in the host for a long time, most healthy individuals rarely present with symptoms because of their immune system. Figures from the Centers for Disease Control and Prevention (CDC) show that more than 40 million individuals in America carry this parasite, which is often referred to as a toxoplasmosis infection. Despite its dormant and asymptomatic state, however, researchers believe that it may play a role in the acceleration of age-related frailty in older individuals. Frailty is characterized by cognitive and physical decline, which often results in exhaustion, weight loss, weakness and slowness, low physical activity and longer recovery time after falling sick as well as increased falls. It is estimated that about 10% of those aged 65 years and older will suffer from frailty, with the figure reaching 25% for those aged 85 and above. The rising toll of frailty among aging populations has inspired companies such as Longeveron Inc. (NASDAQ: LGVN) to devote significant levels of R&D resources to exploring treatments to address the issues that arise due to frailty in old age.

Longeveron Inc. (NASDAQ: LGVN) is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. The Company’s research and therapies are aimed at improving the outcome of infants born with a life-threatening heart condition, as well as improving the healthspan for the aging population – the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging, with function and ability to perform activities of daily living.

Longeveron is involved in clinical trials in the following indications: Hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty.

The Company’s philosophy revolves around the idea that regenerative medicine may hold the potential to improve certain rare medical conditions and contribute to healthy aging. While there has been a remarkable rise in life expectancy over the last century due to medical and public health advancements, this increase in longevity has not been paralleled by the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging.

Longeveron’s lead investigational product is Lomecel-B™, an allogeneic Medicinal Signaling Cell therapy product isolated from the bone marrow of young, healthy adult donors. As humans age, they experience a decrease in immune system function, a decline in blood vessel functioning, chronic inflammation, and other issues. Clinical data has suggested that Lomecel-B™ may address these conditions through multiple mechanisms of action (MOA) that simultaneously target key aging-related processes.

The Company is headquartered in Miami, Florida.

Lomecel-B™

Lomecel-B™ is being evaluated in multiple clinical trials for aging-related chronic diseases and other life-threatening conditions under U.S. FDA-approved Investigational New Drug applications. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas.

The drug is made from special living cells called Medicinal Signaling Cells (MSCs) that are isolated from fresh bone marrow tissue that has been donated by adult donors aged 18 to 45. Once the MSCs have been isolated from the fresh bone marrow through a careful selection process, the cells are culture-expanded (allowed to replicate under controlled laboratory conditions) into the billions using specialized techniques and processes. After a specific number of expansion cycles, called “passages,” the cells are harvested, separated into specific doses (e.g., 50 million cells), and cryopreserved until future use.

These cells have been shown to have characteristics that allow them to be transplanted from a donor to host without triggering a harmful immune response in the recipient, and they can be administered on an outpatient basis in as little as 40 minutes after thawing. Because of these characteristics, Lomecel-B™ is considered an “off-the-shelf” product.

In some trials, such as for Alzheimer’s disease and Aging-related Frailty, Lomecel-B™ is administered via peripheral intravenous infusion, while, in the Company’s HLHS trial, Lomecel-B™ is administered via direct injection into the heart tissue.

Market Opportunity

Longeveron estimates the potential market size for Lomecel-B™ in the treatment of HLHS to be up to $1 billion annually, globally.

U.S. patients suffering from Aging-related Frailty are estimated using U.S. Census Bureau statistics to be approximately 8.1 million. That population potentially represents a market for Lomecel-B™ of between $4 billion and $8 billion globally per year, according to Company estimates.

Additionally, the Alzheimer’s Association puts the number of Americans with that disease at 5.1 million, highlighting another potentially addressable market for Lomecel-B™, that’s worth $5 billion to $10 billion annually.

Management Team

Wa’el Hashad is CEO of Longeveron. He has more than 35 years of experience in the pharmaceutical and biotech industries. He has launched several successful brands in the U.S. and worldwide markets. Prior to joining Longeveron, he was president and CEO of Avanir Pharmaceuticals. Before Avanir, he was the chief commercial officer of Seres Therapeutics. He also has held senior leadership positions at Amgen, Boehringer Ingelheim, and Eli Lilly and Company. He holds a bachelor’s degree in pharmacy from Cairo University and an MBA from the University of Akron.

Joshua M. Hare, M.D., FACC, FAHA, is Co-Founder, Chief Science Officer and Chairman of Longeveron. He is a double board-certified cardiologist and is the founding director of the Interdisciplinary Stem Cell Institute at the University of Miami’s Miller School of Medicine. He is a recipient of the Paul Beeson Physician Faculty Scholar in Aging Research Award and is an elected member of the American Association of Physicians and The American Society for Clinical Investigation. He is also an elected Fellow of the American Heart Association. He received a bachelor’s degree from the University of Pennsylvania and his M.D. from The Johns Hopkins University School of Medicine.

Lisa Locklear is CFO at Longeveron. She previously served as the senior vice president and CFO for Avanir Pharmaceuticals. Prior to Avanir, she held senior financial roles at GSN Games, CoreLogic, Ingram Micro, the Walt Disney Company, and Price Waterhouse, with assignments in Paris and London. She holds a bachelor’s degree in plant science from the University of California, Davis, and an MBA from the University of California, Irvine. She is a licensed CPA (inactive) and is a member of the American Institute of Certified Public Accountants, the California Society of CPAs, and Financial Executives International.

Dr. Nataliya Agafonova, M.D., is the Chief Medical Officer at Longeveron. She previously served as clinical development lead, senior medical director, and product development chair at Otsuka Pharmaceuticals. Before that, she was the clinical development lead and senior medical director at Bristol-Myers Squibb. She previously held senior leadership positions at Ardea Bioscience, Biogen, Amgen, and Genzyme Corporation. She earned an M.D. from the Ukrainian National Medical University and completed her internal medicine residency at Kharkov State University Hospital in Ukraine.

Certain statements in this corporate profile that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “believe,” “expects,” “may,” “looks to,” “will,” “should,” “plan,” “intend,” “on condition,” “target,” “see,” “potential,” “estimates,” “preliminary,” or “anticipates” or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, statements regarding the offer and sale of securities, the terms of the offering, about the ability of Longeveron’s clinical trials to demonstrate safety and efficacy of the Company’s product candidates, and other positive results; the timing and focus of the Company’s ongoing and future preclinical studies and clinical trials and the reporting of data from those studies and trials; the size of the market opportunity for the Company’s product candidates, including its estimates of the number of patients who suffer from the diseases being targeted; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of the Company’s product candidates; the Company’s ability to obtain and maintain regulatory approval of its product candidates in the U.S., Japan and other jurisdictions; the Company’s plans relating to the further development of its product candidates, including additional disease states or indications it may pursue; the Company’s plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and its ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and the Company’s ability to attract and retain such personnel; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s need to raise additional capital, and the difficulties it may face in obtaining access to capital, and the dilutive impact it may have on its investors; the Company’s financial performance and ability to continue as a going concern, and the period over which it estimates its existing cash and cash equivalents will be sufficient to fund its future operating expenses and capital expenditure requirements. Additionally, Longeveron makes no assurance that any public offering of its securities as described herein will occur on the timelines, in the manner or on the terms anticipated due to numerous factors. Further information relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the Company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 14, 2023 and its Quarterly Report on Form 10-Q for the second quarter of 2023 filed with the SEC on August 11, 2023. The forward-looking statements contained in this corporate profile are made as of the date of this corporate profile, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Investor Contact
Mike Moyer
LifeSci Advisors
Tel: 617-308-4306
Email: mmoyer@lifesciadvisors.com

Date prepared: August 31, 2023

Longeveron Inc. (NASDAQ: LGVN), closed Thursday's trading session at $1.82, off by 5.2083%, on 42,442 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.50/$4.5793.

Recent News

• Longeveron Inc. (NASDAQ: LGVN) - Study Links Cat Parasite to Accelerated Frailty in Aging People
• InvestorNewsBreaks - Longeveron Inc. (NASDAQ: LGVN) Featured in Bell2Bell Podcast
• InvestorNewsBreaks - Longeveron Inc. (NASDAQ: LGVN; LGVNR) Study Survival Data Reported at AHA's 2023 Scientific Sessions

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle ("EV") manufacturer, announced that its partner, the Randy Marion Automotive Group ("RMA"), has received its North Carolina license to retail Mullen's commercial EVs. According to the announcement, this is a required dealer license that allows the auto group to move vehicles to customers. According to RMA officials, the organization is seeing "tremendous interest" in Mullen's Class 1 and Class 3 vehicles. The new dealer license allows the company to immediately begin delivering Mullen EVs. Beginning Nov. 20, 2023, the company will begin shipping Class 3 vehicles to Adventure Coast Rentals in Tennessee and Georgia, Godotek in Michigan and NRTC Automation Group in Alabama. RMA also anticipates receiving a new shipment of completed vehicles from Mullen. The vehicles in that shipment are all presold and will go to Duke Energy, Merchants Fleet and MGT Leasing. Mullen noted that the Class 1 vehicle production line at its Tunica assembly plant began on Nov. 1, 2023, and the company is now running both Class 1 and Class 3 production lines simultaneously at the facility, with plans to deliver 150 Class 3 and 300 Class 1 vehicles by the end of this year. "It's exciting to see both Class 1 and Class 3 vehicle production fully operational and our Class 3 heading to customers," said Mullen Automotive CEO David Michery in the press release. "We fully expect to accomplish our production and delivery goals for 2023."

To view the full press release, visit https://ibn.fm/ZbZGF

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Thursday's trading session at $0.175, off by 1.9058%, on 37,751,897 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.1701/$107.4375.

Recent News

• Mullen Automotive Inc. (NASDAQ: MULN) - InvestorNewsBreaks - Mullen Automotive Inc. (NASDAQ: MULN) Partner Receives Key Retail License, Begins Shipping EVs
• InvestorNewsBreaks - Mullen Automotive Inc. (NASDAQ: MULN) Announces Expansion of US Battery Operations
• Rich Millennials View EVs as a Status Symbol

Correlate Energy Corp. (OTCQB: CIPI)

The QualityStocks Daily Newsletter would like to spotlight Correlate Energy Corp. (OTCQB: CIPI).

Correlate Energy Corp. (OTCQB: CIPI) is a publicly-traded company strategically positioned to capitalize on America’s unstoppable trend toward decentralized energy generation.

The energy grid in the U.S. is insufficient for the booming clean energy trend, and current infrastructure is limiting green energy distribution. Constructing the needed infrastructure to address this demand imbalance will cost billions and be far too slow, positioning decentralized systems, like those on offer from Correlate, in a key position for heightened demand.

Correlate has identified several key economic drivers powering the decentralized energy trend, including:

1. Real Cost Savings – Customer pays zero money down and gets an instant electrical price discount to current rates.
2. Massive Project Investment Funding – The International Energy Agency estimates that over one billion dollars per day will be invested in solar energy in 2023.
3. Consistent Long-Term Incentives – The Inflation Reduction Act is a game-changer, supercharging renewables with $1.2 trillion in tax credits for 10 years of market support.
4. Robust Customer Demand – Wood Mackenzie expects the U.S. solar industry to nearly triple in size over the next five years.

Correlate’s team of multi-decade experts who have worked with renowned global brands are positioning the company to make the most of this opportunity while consolidating a fragmented industry. Collectively, the team has developed, financed and deployed over $2 billion in clean energy projects to date.

Three-Pronged Strategy

Correlate is leveraging a three-pronged strategy aimed at driving shareholder value:

1. Sell – Correlate seeks to finance, develop and profitably sell localized clean energy solutions and microgrids to industrial, commercial and residential customers.
2. Retain – Correlate plans to retain ownership of some of these energy systems and thereby realize ongoing, reliable cash flow.
3. Acquire – Correlate seeks to acquire proven renewable energy companies in order to exponentially grow earnings per share for investors.

This strategy is enhanced by current investment trends. Clean energy earnings are being sought after by investors. In Q4 2022, the median EBITDA multiple for green energy companies was 12.3x, according to Finerva.

Market Outlook

Over the next decade and beyond, renewable energy growth is expected to come primarily via decentralized systems like those offered by Correlate.
The Inflation Reduction Act enacted in late August 2022 is likewise expected to drive growth for the company by providing new tax incentives that reduce costs for clients and/or elevate returns to investors.

Commercial buildings consume more than 35% of the generated electricity in the U.S. and are underperforming in energy efficiency at every level. These buildings waste energy, emit too much carbon and are too costly for owners and occupants, but retrofits are not happening at the rate or scale needed.

In today’s real estate market, portfolio property owners own most commercial buildings, yet most building efficiency work is focused on single buildings, thereby missing the distinct needs of this owner class which are very different from traditional owner-occupiers. The diverse nature of commercial buildings, combined with technology and performance uncertainty, make simple energy optimization initiatives – which could greatly reduce energy use and improve building value – financially unattractive, resulting in slow adoption rates. CIPI’s financial instruments and software breakdown this issue, known as the ‘split incentive’, unlocking the majority of the addressable market.

A key portion of Correlate’s strategy relates to consolidation of what has been a fragmented industry. By uncovering opportunities to improve efficiencies through strategic M&A activities, the company intends to enhance profitability throughout its operations.

Management Team

Todd Michaels is President and CEO of CIPI and founder of Correlate. He formerly served as Vice President for Innovation at SunEdison and Senior Director Distributed Solar at NRG Energy. He founded Correlate in 2015 and has 16 years of experience in the energy industry. He graduated from Indiana University with a B.S. in Computer Information Systems.

Channing Chen is CFO at CIPI and Correlate Inc. and brings over 16 years of experience in the solar industry as a developer, financier, and business unit leader. He has held executive management roles at Solar Power Partners (acquired by NRG Energy), where he was a founding employee, SunEdison, and NRG Energy (NYSE: NRG). Most recently, Mr. Chen was founder and Managing Partner at Breakaway Energy Partners LLC – a distributed energy financing and market-making platform. To date, Mr. Chen and his teams have raised over $1.5 billion in financing across residential, commercial, and utility scale solar and energy storage projects representing over 400 MWs. He holds a B.A. in Environmental Chemistry from the University of California at San Diego and an MBA from the University of Southern California. He is also an advisor and early-stage investor to several startup companies in the renewable energy space.

Dave Bailey is Chief Revenue Officer of Correlate Inc. With over 15 years of executive sales, supply chain management, and energy efficiency experience, he is responsible for ensuring the success of the National Commercial Sales Unit across multiple regional project teams. Mr. Bailey created and launched the Transformation Services team while at Wesco for its multibillion-dollar Distributed Energy Resource division, formerly Westinghouse. His focus was on IoT-enabled efficiency and plant floor automation-based services. Before that, he spent several years in Global Account Sales Management, with GE Supply as a Program Manager, and is a Commercial Leadership Program graduate. Mr. Bailey received his B.S. in Mechanical Engineering from the University of Kentucky.

Jed Freedlander is the company’s Chief Development Officer. He has a background in infrastructure development and investment and a strong legal, commercial and finance acumen. Mr. Freedlander has a proven track record in leading complex public-private partnership (P3) and energy transactions and is instrumental in driving Correlate’s strategic development initiatives.

Roger Baum is Executive VP Operations at Correlate. With over 20 years of experience at Core Construction, he brings to the company a wealth of knowledge and a strong track record in delivering successful commercial construction projects.

Jason Loyet is Director of Solar Energy for Correlate Inc. He is a cleantech executive with over 20 years of experience leading high growth solar energy and software start-ups. Mr. Loyet is a U.S. Department of Energy SunShot Catalyst award winner for his work building the Solar Site Design technology platform. Before joining the solar energy industry in 2005, he founded and sold two software companies in the streaming media (GlobalStreams) and newspaper publishing (MyCapture) industries. Mr. Loyet currently serves as a Member of the Board of Directors for the Tennessee Solar Energy Industry Association (TenneSEIA).

Correlate Energy Corp. (OTCQB: CIPI), closed Thursday's trading session at $1.65, up 5.7692%, on 304 volume. The average volume for the last 3 months is 4,907 and the stock's 52-week low/high is $0.3501/$2.35.

Recent News

• Correlate Energy Corp. (OTCQB: CIPI) - InvestorNewsBreaks - Correlate Energy Corp. (CIPI) Spotlighted in New Harbinger Research Report
• InvestorNewsBreaks - Correlate Energy Corp. (CIPI) Holds Live Investor Summit Webinar to Discuss Microgrid Deal with California Oil and Gas Company
• Harbinger Research Publishes New Research Report on Correlate Energy Corp., a Rapidly Growing Provider of Sustainable Energy Solutions Based on Solar Generation and Battery Storage Systems

FingerMotion Inc. (NASDAQ: FNGR)

The QualityStocks Daily Newsletter would like to spotlight FingerMotion Inc. (NASDAQ: FNGR) .

FingerMotion Inc. (NASDAQ: FNGR) is an evolving technological company with core competencies in mobile payment and recharge platform solutions in China. FingerMotion is in the process of developing additional value-added technologies to market to users.

Founded in 2016, FingerMotion’s goal is to serve over a billion users in the Chinese market and expand its model to other regional markets. The company has offices in Hong Kong, Shanghai and New York City.

Current Offerings

FingerMotion is analyzing and transforming mobile data to improve the lifestyle of the public through technology and innovation. The company’s current offerings include:

• Telecommunications Products and Services – FingerMotion’s proprietary universal exchange platform, ‘PigeonHole Integration System (PIS)’, offers seamless integration between telecom operators and online stores. The service platform’s offerings include top up and recharge, data plan, mobile phone, loyalty points redemption and subscription plans. The platform offers reliable and secure transactions, real-time reconciliation, simple integration for partners and efficient settlements.
• SMS and MMS Services – The integrated platform is registered as FingerMotion’s IP in China and provides a robust back-end control panel for corporate partners to manage their own messaging settings. FingerMotion’s clients range from insurance to financial industries, ecommerce firms, airlines and more. The platform offers competitive pricing for partners and provides quick and efficient review to meet timely marketing initiatives.
• Big Data Insights – FingerMotion brings Big Data-enabled insurance solutions through its Big Data Insights arm, Sapientus. The company’s strategic partnerships with the largest Chinese telecommunications giants allow access to uncover behavior insights through geolocation and mobile data usage. Its Big Data offerings include risk scoring, precise marketing, simplified underwriting and customized products.
• Rich Communication Services (RCS) – FingerMotion’s RCS platform will be a proprietary business messaging solution that enables businesses and brands to communicate their services to customers via 5G infrastructure. The company expects its RCS platform to offer a better user experience, more efficiency and cost-effectiveness when compared to other solutions.

Telecommunications and Insurtech Markets

The global telecommunications market was valued at $1.74 trillion in 2019 and is expected to grow at a CAGR of 5% from 2020 to 2027. The steady increase is expected to be driven by the adoption of 5G and the increased popularity of Internet of Things (IoT) applications.

The Chinese telecom market was valued at $254.1 billion in 2017 and is also constantly expanding. The current Chinese telecom market is dominated by three mobile operators – China Mobile, China Unicom and China Telecom, which together are responsible for around 1.6 billion active subscribers (https://ibn.fm/zfwy9).

In addition, the insurtech (insurance technology) market was valued at $2.72 billion globally in 2020 and is expected to grow at a CAGR of 48.8% from 2021 to 2028. The large increase is attributed to the rising use of technology solutions for everyday activities like acquiring insurance coverage (https://ibn.fm/TGo7D).

Through its proprietary platforms and technologies, FingerMotion is uniquely positioned to capitalize on the telecom and insurtech markets’ growth and opportunities.

Management Team

Martin J. Shen is the Chief Executive Officer of FingerMotion Inc. He has over 15 years of experience in senior management roles within entrepreneurial startups and large multinational corporations. He has acquired a wide range of corporate management, financial oversight and operation administration expertise through these roles. In his most recent role, he founded Imperial Distributors (formerly known as AP Martin Pharmaceutical Supplies Ltd.), establishing the company as the preferred choice for distributional support to regional pharmacies throughout Western Canada. Before founding Imperial, Mr. Shen served as the Chief Operating Officer and Chief Financial Officer at Wales and Son Industrial (formerly Weir Minerals), a firm specializing in global delivery and support for mining slurry equipment. He began his career at PricewaterhouseCoopers in Vancouver, with work tours in the tax department in Singapore and the tax audit and advisory group in Hong Kong. Mr. Shen is a U.S. Certified Public Accountant and holds a Bachelor of Science from the University of British Columbia.

Lee Yew Hon is the company’s Chief Financial Officer. From 2006 until November 2020, he was the Chief Financial Officer of Cubinet Interactive Group of Companies, and he also took on the Chief Operating Officer role in 2011. During his tenure, he was instrumental in leading Cubinet and building teams across the Southeast Asia region, setting up financial processes within a short time. Mr. Lee spearheaded the growth of Cubinet to other regions, including Europe, the Middle East and Russia. He received his diploma from Tunku Abdul Rahman College in 1996. He is a Chartered Accountant, a member of the Malaysia Institute of Accountants (MIA) and an Associate Member of the Chartered Institute of Management Accountants, UK (ACMA).

Li Li is the Senior Vice President of FingerMotion. She recently served as Advisor to Shenzhen WuYiKa Technology Co. Ltd., a comprehensive service platform dedicated to online service distribution and payment. The company has become a fast and efficient provider of new media marketing solutions for the mobile internet. She has held high-level management positions with multiple industry names, including Hangzhou JiuYue Information Technology Co. Ltd. and Hangzhou LingXuan Information Technology. Ms. Li started her career in 2004, founding Shanghai ChuangYeZZ Network Technology Co. Ltd. and serving as its Vice President. With the close cooperation of local operators, the company launched SMS, MMS, WAP, mobile JAVA games, Hunan Satellite TV e-magazine and other wireless internet services to meet the rapid development of wireless internet and application requirements. She received her degree from Nanjing Academy of Engineering.

FingerMotion Inc. (FNGR), closed Thursday's trading session at $4.7, off by 4.4715%, on 369,722 volume. The average volume for the last 3 months is 1.004M and the stock's 52-week low/high is $1.01/$7.97.

Recent News

• FingerMotion Inc. (NASDAQ: FNGR) - InvestorNewsBreaks - FingerMotion Inc. (NASDAQ: FNGR) Announces Filing of Federal Lawsuit Against Research Firm
• InvestorNewsBreaks - FingerMotion Inc. (NASDAQ: FNGR) Announces Q2 2024 Results
• InvestorNewsBreaks - FingerMotion Inc. (NASDAQ: FNGR) Retains Attorney Mark R. Basile, Esq. and The Basile Law Firm P.C.

Electronic Servitor Publication Network Inc. (OTCQB: XESP)

The QualityStocks Daily Newsletter would like to spotlight Electronic Servitor Publication Network Inc. (OTCQB: XESP).

Electronic Servitor Publication Network Inc. (OTCQB: XESP) is a digital engagement company offering a managed service which provides digital activation and engagement solutions to companies that seek to optimize their growth. Its managed service is powered by a proven, proprietary technology – the Digital Engagement Engine™. This technology provides intelligent interaction management, dynamic content provisioning, and a logic-driven workflow, which creates digital experiences that accelerate an audience from awareness to action – driving growth.

Electronic Servitor Publication Network’s services are designed to drive growth for both established and developing organizations. Through the optimization of digital interactions within current and new communities, the Digital Engagement Engine™ ensures that client content is relevant, reaches the right audience, and connects with the intended person at the right time.

The company calls it ‘Growth as a Service’.

Client implementation is nearly effortless, since the solution is completely managed by the Electronic Servitor Publication Network team. This business model allows clients to focus on their brands, core product offerings, and content creation, while the company manages the technology and outcome.

The company is headquartered in Minneapolis, Minnesota.

Technology

Electronic Servitor Publication Network’s Digital Engagement Engine™ utilizes a combination of automation, unique data management, and a modern workflow built on a microservices architecture to achieve greater reach and lift. Using sophisticated data analysis and smart technology, the Digital Engagement Engine™ provides companies with the ability to maintain complete control of their content while creating meaningful relationships with new customers and revenue streams.

The Digital Engagement Engine™ isn’t just another marketing or technology tool; it’s a way to develop real connections with target markets.

Market Outlook

According to a report by ReportLinker.com, an award-winning market research firm, the global customer engagement solutions market was estimated at $19.3 billion in 2022 and is forecast to grow to $32.2 billion by 2027, achieving a CAGR of 10.8% during the forecast period.

The report notes that these engagement solutions are vital to companies seeking to widen their customer bases, reduce customer churn rates and increase customer retention. These perceived benefits of customer engagement solutions are likely to drive their growing adoption around the globe during the forecast period, according to the report.

Management Team

Peter Hager is President and CEO of Electronic Servitor. He joined the company from Pointward Inc., a medtech customer engagement agency that provided solutions to drive market entry, growth, and commercialization for Fortune 500 health care brands and medtech startups. He has founded and managed multiple technology, professional services and medtech organizations throughout his career. Mr. Hager holds a bachelor’s degree from Macalester College in St. Paul, Minnesota, with concentrations in economics and psychology.

Jim Kellogg is CFO of Electronic Servitor. He has served as the principal of J. Kellogg & Company Inc., a business and tax consultant, since 2005. He has provided legal support to clients’ business valuations, business interruption and divorce property valuations. He has worked as a professional tax adviser since 1983. Mr. Kellogg obtained his JD with emphasis on taxation from Western State University College of Law and was certified as a financial planner by the College for Financial Planning in 1990.

Thomas (Denny) Spruce, RPh, is COO of Electronic Servitor. He oversees company infrastructure, regulatory reporting, and strategic partner relationships, among other roles and responsibilities. He joined the company in March 2022 and, since that time, has implemented foundational support processes, developed contractual relationships with service providers, managed financial and regulatory reporting and overseen contract development and management with the legal team. Mr. Spruce obtained a BS in Pharmacy from the University of Arkansas.

Electronic Servitor Publication Network Inc. (XESP), closed Thursday's trading session at $0.195, even for the day. The average volume for the last 3 months is 5,010 and the stock's 52-week low/high is $0.03/$0.22.

Recent News

• Electronic Servitor Publication Network Inc. (OTCQB: XESP) - InvestorNewsBreaks - Electronic Servitor Publication Network Inc. (XESP) Acquires Pointward Inc. Technologies
• InvestorNewsBreaks - Electronic Servitor Publication Network Inc. (XESP) to Acquire Assets of PhiTech Management LLC
• InvestorNewsBreaks - Electronic Servitor Publication Network Inc. (XESP) Announces Participation at Emerging Growth Conference